MoonLake Immunotherapeutics Class A (MLTX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Immunologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 31/100 (MEDIUM), 44.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 23.39% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
- MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
- MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
- MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
- Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
- MoonLake Immunotherapeutics' CFO Sells 39K Shares
- MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa
- How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for MoonLake Immunotherapeutics Class A.
Full MLTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.